AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34610254 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 121
Study 34610254 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 121
Study 34610254 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 121
Study 34610254 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Timolol and Latanoprost
Number of subjects: 121
Study 32771106 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (early surgical fixation)
Number of subjects: 439
Study 32771106 — intervention group
Group type: COMPARATOR
Intervention: Cast immobilisation
Number of subjects: 439
Study 34741280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil (600 mg every 12 hours or 600 mg every 8 hours)
Number of subjects: 1808
Study 34741280 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin plus aztreonam (1 g every 12 hours for vancomycin and 1 g every 8 hours for aztreonam)
Number of subjects: 1808
Study 32285709 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT) for 14 days by enemas from five faecal donors
Number of subjects: 9
Study 32285709 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 9
Study 36173041 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (14 days)
Number of subjects: 20
Study 36173041 — intervention group
Group type: COMPARATOR
Intervention: Gluten-containing diet (14 g/day gluten for 14 days)
Number of subjects: 20
Study 36173041 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 20
Study 33030391 — intervention group
Group type: COMPARATOR
Intervention: Test supplement
Number of subjects: 43
Study 33030391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 33150745 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHAG (gonadotropin‐releasing hormone agonist) for 24 weeks (n = 14)
Number of subjects: 34
Study 33150745 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHAG + Exercise for 24 weeks (n = 11)
Number of subjects: 34
Study 33150745 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks (n = 9)
Number of subjects: 34
Study 33272351 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted allele score MR (WAS‐MR)
Number of subjects: 0
Study 33272351 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse variance weighted MR (IVW‐MR)
Number of subjects: 0
Study 33272351 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted median MR (WM‐MR)
Number of subjects: 0
Study 33272351 — intervention group
Group type: EXPERIMENTAL
Intervention: MR‐Egger
Number of subjects: 0
Study 33272351 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional analysis framework utilizing maternal and offspring genotypes
Number of subjects: 0
Study 33123853 — intervention group
Group type: EXPERIMENTAL
Intervention: Activating spinal orthosis
Number of subjects: 18
Study 33162369 — intervention group
Group type: EXPERIMENTAL
Intervention: GA-guided multidisciplinary clinic recommendations (decline, defer, proceed)
Number of subjects: 91
Study 33162369 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoHCT recipients
Number of subjects: 91
Study 33162369 — intervention group
Group type: EXPERIMENTAL
Intervention: GA-identified functional deficits (frail grip strength, poor performance status)
Number of subjects: 91
Study 33162369 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients deferred but ultimately receiving autoHCT
Number of subjects: 91
Study 32229469 — intervention group
Group type: EXPERIMENTAL
Intervention: Push notifications related to mood
Number of subjects: 1565
Study 32229469 — intervention group
Group type: EXPERIMENTAL
Intervention: Push notifications related to activity
Number of subjects: 1565
Study 32229469 — intervention group
Group type: EXPERIMENTAL
Intervention: Push notifications related to sleep
Number of subjects: 1565
Study 35078574 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin (50, 100, 200, 400 ng/mL)
Number of subjects: 0
Study 35078574 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin (after knockdown of MMP14 and leptin receptor genes)
Number of subjects: 0
Study 35078574 — intervention group
Group type: COMPARATOR
Intervention: Control group (no leptin treatment)
Number of subjects: 0
Study 34605920 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 764
Study 34605920 — intervention group
Group type: EXPERIMENTAL
Intervention: Process
Number of subjects: 764
Study 34605920 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcomes
Number of subjects: 764
Study 34605920 — intervention group
Group type: EXPERIMENTAL
Intervention: Process plus Outcomes
Number of subjects: 764
Study 34643808 — intervention group
Group type: EXPERIMENTAL
Intervention: SPPF plus EMD
Number of subjects: 13
Study 34643808 — intervention group
Group type: COMPARATOR
Intervention: SPPF alone
Number of subjects: 13
Study 34267461 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboelastometry-based protocol (ROTEM)
Number of subjects: 80
Study 34267461 — intervention group
Group type: COMPARATOR
Intervention: Routine practices including conventional coagulation testing and clinical judgments (Control)
Number of subjects: 80
Study 34939265 — intervention group
Group type: EXPERIMENTAL
Intervention: Audience Response System (ARS)
Number of subjects: 83
Study 34939265 — intervention group
Group type: COMPARATOR
Intervention: Traditional Lecture
Number of subjects: 83
Study 34939265 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ARS and Traditional Lecture
Number of subjects: 83
Study 34939265 — intervention group
Group type: EXPERIMENTAL
Intervention: ARS
Number of subjects: 83
Study 32144973 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural Mobilization Group (NMG)
Number of subjects: 41
Study 32144973 — intervention group
Group type: COMPARATOR
Intervention: Electrotherapy Group (ETG)
Number of subjects: 41
Study 33123587 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 1052
Study 33123587 — intervention group
Group type: COMPARATOR
Intervention: Control group (diet and exercise instruction)
Number of subjects: 1052
Study 33123587 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral Chinese and western medicine)
Number of subjects: 1052
Study 35757326 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (10 mcg/kg/day subcutaneously)
Number of subjects: 37
Study 35757326 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mL of 0.9% saline subcutaneously)
Number of subjects: 37
Study 33837422 — intervention group
Group type: EXPERIMENTAL
Intervention: e-cigarettes
Number of subjects: 64
Study 35954716 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic
Number of subjects: 0
Study 35954716 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic (women)
Number of subjects: 0
Study 35954716 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic (men)
Number of subjects: 0
Study 33579631 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument tray optimization using Lean methodology
Number of subjects: 35
Study 35830173 — intervention group
Group type: EXPERIMENTAL
Intervention: Berdazimer gel, 10.3%
Number of subjects: 891
Study 35830173 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 891
Study 32046952 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35486590 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive community facilities
Number of subjects: 0
Study 35486590 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated community facilities
Number of subjects: 0
Study 35486590 — intervention group
Group type: COMPARATOR
Intervention: Community facilities
Number of subjects: 0
Study 35486590 — intervention group
Group type: COMPARATOR
Intervention: Academic facilities
Number of subjects: 0
Study 35486590 — intervention group
Group type: EXPERIMENTAL
Intervention: Community centers post-Z0011 trial
Number of subjects: 0
Study 34029680 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg/d
Number of subjects: 4401
Study 34029680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4401
Study 32685547 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI) assessment in caregivers
Number of subjects: 551
Study 32685547 — intervention group
Group type: COMPARATOR
Intervention: Sleep duration and habitual sleep efficiency in caregivers
Number of subjects: 551
Study 32238014 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (20 mg/d) plus topical treatments (clobetasol 0.05% and tacrolimus 0.1%)
Number of subjects: 38
Study 32238014 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with topical treatments (clobetasol 0.05% and tacrolimus 0.1%)
Number of subjects: 38
Study 33635735 — intervention group
Group type: EXPERIMENTAL
Intervention: ART initiation regardless of CD4 count
Number of subjects: 134
Study 33635735 — intervention group
Group type: EXPERIMENTAL
Intervention: Health worker communication
Number of subjects: 134
Study 32737891 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of preventive dental services
Number of subjects: 638
Study 32737891 — intervention group
Group type: EXPERIMENTAL
Intervention: Being a former smoker
Number of subjects: 638
Study 32737891 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report of very poor/poor oral health
Number of subjects: 638
Study 32737891 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report of fair oral health
Number of subjects: 638
Study 32737891 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported dental disease
Number of subjects: 638
Study 32737891 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported gingival disease
Number of subjects: 638
Study 35747237 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic mesenchymal stem/stromal cells (MSC)
Number of subjects: 14
Study 35747237 — intervention group
Group type: COMPARATOR
Intervention: High molecular weight hyaluronic acid (HA)
Number of subjects: 14
Study 33218556 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical Swedish massage (7 minutes on each posterior thigh for 5 consecutive days)
Number of subjects: 34
Study 33218556 — intervention group
Group type: COMPARATOR
Intervention: Superficial stroking (control group)
Number of subjects: 34
Study 37267172 — intervention group
Group type: EXPERIMENTAL
Intervention: Video directly observed therapy (video DOT) for 12 weeks via a mobile health technology platform
Number of subjects: 39
Study 37267172 — intervention group
Group type: EXPERIMENTAL
Intervention: Video directly observed therapy (video DOT)
Number of subjects: 39
Study 33107163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 60
Study 33107163 — intervention group
Group type: COMPARATOR
Intervention: Sleep Deprivation
Number of subjects: 60
Study 34674397 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 76
Study 34674397 — intervention group
Group type: COMPARATOR
Intervention: Room air insufflation
Number of subjects: 76
Study 34108586 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography screening
Number of subjects: 788897
Study 33807135 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat (HF) dairy group incorporating ≥3 servings/day
Number of subjects: 111
Study 33807135 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat (LF) dairy group incorporating ≥3 servings/day
Number of subjects: 111
Study 33807135 — intervention group
Group type: COMPARATOR
Intervention: Control group maintaining baseline dairy intake
Number of subjects: 111
Study 35459259 — intervention group
Group type: EXPERIMENTAL
Intervention: PPFP intervention
Number of subjects: 21000
Study 35459259 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 21000
Study 33515489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa‐2b
Number of subjects: 0
Study 33515489 — intervention group
Group type: COMPARATOR
Intervention: Phlebotomy
Number of subjects: 0
Study 32250672 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing Prescriptions as Health Care (integrating priority placement in affordable housing and provision of services such as case management, financial, and legal services)
Number of subjects: 78
Study 32250672 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (providing resource guides and hospital‐based social work or care navigation services)
Number of subjects: 78
Study 36267872 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropifexor 30 μg
Number of subjects: 61
Study 36267872 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropifexor 60 μg
Number of subjects: 61
Study 36267872 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropifexor 90 μg
Number of subjects: 61
Study 36267872 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropifexor 150 μg
Number of subjects: 61
Study 36267872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 36267872 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropifexor (all doses)
Number of subjects: 61
Study 32665587 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization estimates using unrelated individuals
Number of subjects: 283376
Study 32665587 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-family Mendelian randomization analyses
Number of subjects: 283376
Study 35701800 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 20
Study 35701800 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate
Number of subjects: 20
Study 34153228 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy inhaler
Number of subjects: 44
Study 33327697 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal airway
Number of subjects: 148
Study 33327697 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway
Number of subjects: 148
Study 36271352 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ketamine (0.5 mg/kg)
Number of subjects: 23
Study 36271352 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (40-min infusion)
Number of subjects: 23
Study 36271352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 34487870 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 4 or 8 weeks
Number of subjects: 446
Study 34487870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 446
Study 33609052 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 135
Study 33609052 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 135
Study 34274006 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative process evaluations of recruitment strategies in the ACTIVE and PRESTO studies.
Number of subjects: 59
Study 34274006 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative semi-structured interviews with patients and health professionals.
Number of subjects: 59
Study 35798228 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 1 (geometric cloud mapping)
Number of subjects: 0
Study 35798228 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 2 (quantitative measurements from Camp et al)
Number of subjects: 0
Study 35798228 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 3 (quantitative measurements from Frangiamore et al)
Number of subjects: 0
Study 35798228 — intervention group
Group type: COMPARATOR
Intervention: Geometric cloud technique
Number of subjects: 0
Study 35798228 — intervention group
Group type: EXPERIMENTAL
Intervention: Humeral anchor deviations
Number of subjects: 0
Study 32513905 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐FLT PET
Number of subjects: 18
Study 32513905 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE
Number of subjects: 18
Study 34676424 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 7017
Study 34676424 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 7017
Study 34904132 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizanlizumab
Number of subjects: 0
Study 34904132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32662191 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 200
Study 32662191 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 200
Study 33964910 — intervention group
Group type: EXPERIMENTAL
Intervention: remestemcel‐L
Number of subjects: 29
Study 33964910 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29
Study 36163942 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamibarotene/Azacitidine
Number of subjects: 190
Study 36163942 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Azacitidine
Number of subjects: 190
Study 33823928 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPS + exercise
Number of subjects: 0
Study 33823928 — intervention group
Group type: COMPARATOR
Intervention: exercise
Number of subjects: 0
Study 32026323 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct texting method
Number of subjects: 103
Study 32026323 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse screening method
Number of subjects: 103
Study 32026323 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trial
Number of subjects: 103
Study 33078338 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted revisional bariatric surgery (R-RBS)
Number of subjects: 167
Study 34031987 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training program for social workers
Number of subjects: 1384
Study 34358673 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic compression stockings (ECS)
Number of subjects: 232
Study 34358673 — intervention group
Group type: COMPARATOR
Intervention: Control group (not wearing ECS)
Number of subjects: 232
Study 35317213 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based physical exercise program (14 weeks, unsupervised, self-selected frequency and duration)
Number of subjects: 110
Study 35317213 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 110
Study 32247709 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching comedy videos
Number of subjects: 88
Study 32247709 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 88
Study 35797863 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 72
Study 35797863 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 72
Study 34180702 — intervention group
Group type: EXPERIMENTAL
Intervention: Prodromal symptoms (binge eating, compensatory behaviors, weight/shape overvaluation, fear of weight gain, feeling fat)
Number of subjects: 1952
Study 34180702 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight/shape overvaluation, fear of weight gain, lower than expected body mass index
Number of subjects: 1952
Study 34180702 — intervention group
Group type: EXPERIMENTAL
Intervention: Prodromal symptoms and established risk factors
Number of subjects: 1952
Study 33827653 — intervention group
Group type: EXPERIMENTAL
Intervention: VR immersion group
Number of subjects: 30
Study 33827653 — intervention group
Group type: COMPARATOR
Intervention: Routine night-shift group
Number of subjects: 30
Study 32246953 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 40
Study 32246953 — intervention group
Group type: COMPARATOR
Intervention: Fingerprick glucose monitoring
Number of subjects: 40
Study 32246953 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CGM and fingerprick)
Number of subjects: 40
Study 32246953 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of glucose testing and booklet entry
Number of subjects: 40
Study 35762503 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 101
Study 35762503 — intervention group
Group type: COMPARATOR
Intervention: Darunavir/cobicistat
Number of subjects: 101
Study 36087586 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg R21/25 μg Matrix‐M
Number of subjects: 409
Study 36087586 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg R21/50 μg Matrix‐M
Number of subjects: 409
Study 36087586 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (Rabivax‐S rabies vaccine)
Number of subjects: 409
Study 32449213 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan (50 mg, 100 mg, 200 mg)
Number of subjects: 158
Study 32449213 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan (100 mg, 200 mg)
Number of subjects: 158
Study 32449213 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (1 mg)
Number of subjects: 158
Study 32449213 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine (50 mg)
Number of subjects: 158
Study 32449213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 35998947 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine-Ketorolac combination (1 mg/kg IV meperidine and 30 mg IV ketorolac)
Number of subjects: 88
Study 35998947 — intervention group
Group type: COMPARATOR
Intervention: Meperidine alone (1 mg/kg IV meperidine)
Number of subjects: 88
Study 36264909 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady Feet (SF) exercise programme
Number of subjects: 260
Study 36264909 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 260
Study 33495093 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) distraction
Number of subjects: 20
Study 33495093 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 20
Study 34575292 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% with 1:200,000 epinephrine plus 2 mL of clonidine 1 µg/kg and normal saline 0.9% (Group 2)
Number of subjects: 24
Study 34575292 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% with 1:200,000 epinephrine plus 2 mL of normal saline 0.9% (Group 1)
Number of subjects: 24
Study 33295294 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural language processing (NLP) for extracting clinical text entities from pathology reports
Number of subjects: 1848
Study 33295294 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping extracted clinical and genetic information to OMOP CDM
Number of subjects: 1848